Health Minister Hsueh Jui-yuan (薛瑞元) said Wednesday the ministry's commissioning of Choice Pharma Taiwan to conduct Phase 2 clinical trials of the locally manufactured Medigen COVID-19 vaccine predated a merger between Choice Pharma's parent company and a Shanghai-based firm, amid controversy over possible Chinese involvement in the trials.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Cross-Strait
Taiwan refutes China 'cyberattack' allegation
03/17/2025 06:24 PM - Science & Tech
Trump's goal of U.S. chip self-sufficiency unrealistic: Japan expert
03/17/2025 06:13 PM - Cross-Strait
U.S. report raises concern over Evergreen sourcing ships from China
03/17/2025 06:05 PM - Business
Taiwan shares end up ahead of Nvidia's conference
03/17/2025 05:34 PM - Culture
Taiwanese actors win best supporting accolades at Asian Film Awards
03/17/2025 05:14 PM